Effect of misoprostol (PGE1) on glucose metabolism in type-2-diabetic and control subjects

N. A. Lee, M. Matsuda, P. Bressler, T. Pratipanawatr, L. Glass, L. J. Mandarino, R. A. DeFronzo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


In vitro and in vivo studies have demonstrated that prostaglandins of the E series enhance muscle glucose uptake. We examined the effect of acute misoprostol (PGE1) administration on whole body insulin-mediated glucose disposal, as well as the major intracellular pathways of glucose metabolism in type 2 diabetic (n=10) and non-diabetic (n=4) subjects. Each subject received two 240-min euglycaemic insulin (40 mU/m2/min) clamp studies with tritiated glucose and indirect calorimetry. During one of the insulin clamp studies, 200 μg of misoprostol was ingested at 90 and 150 min after the start of the insulin infusion. Insulin-mediated total body glucose disposal, glycolysis, glycogenesis and glucose oxidation were similar during the insulin clamp studies performed without and with misoprostol in both the diabetic and non-diabetic groups. These results demonstrate that the acute administration of misoprostol does not enhance insulin-mediated glucose disposal in either type-2-diabetic or non-diabetic subjects.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalDiabetes, Obesity and Metabolism
Issue number3
StatePublished - 2002
Externally publishedYes


  • Glucose metabolism
  • Insulin resistance
  • Misoprostol (PGE1)
  • Prostglandin E1
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this